Risk of pulmonary toxicities in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and meta-analysis of phase 3 randomized controlled trials.

Authors: Abbas Hussain, Hazem Aboaid, Riccesha Hattin, Savannah Schauer, Tel Schl, Rory Twells, Karl Aharonian, Ryan Parto, Rodd Rahmani, Chalette Lambert-Swainston, Ramaditya Srinivasmurthy, Daniel Thomas Jones, Kyaw Zin Thein

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e24035

Source: Full article

---

Abstract

e24035